Skip to content

Multicentre trial of anti-D administration for preventing rhesus alloimmunisation in China

Multicentre trial of anti-D administration for preventing rhesus alloimmunisation in China

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ORC-17013422
Enrollment
Unknown
Registered
2017-11-16
Start date
2017-01-01
Completion date
Unknown
Last updated
2017-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhesus maternal fetal blood group incompatibility hemolytic disease of the new born

Interventions

Experimental group:Anti-d immunoglobulin
Control group:no

Sponsors

The First People's Hospital of Neijiang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) the rh-negative maternal and her husband were Rh positive; (2) multigravida who have had more than 28 weeks of pregnancy (3) there are no other obstetric complications;;Inclusion criteria: (1) the rh-negative maternal and her husband were Rh positive; (2) multigravida who have had more than 28 weeks of pregnancy (3) there are no other obstetric complications;

Exclusion criteria

Exclusion criteria: (1) for Rh positive maternal (2) for primigravida; (3) merger with other obstetric complications;;Exclusion criteria: (1) for Rh positive maternal (2) for primigravida; (3) merger with other obstetric complications;

Design outcomes

Primary

MeasureTime frame
Neonatal birth and gestational week;Newborn weight;Newborn Apgar score;Neonatal jaundice;;Neonatal birth and gestational week;Newborn weight;Newborn Apgar score;Neonatal jaundice;

Countries

China

Contacts

Public ContactXie Xiaohui;Xie Xiaohui ;

The First People's Hospital of Neijiang;The First People's Hospital of Neijiang

xiexiaohui9999@163.com;xiexiaohui9999@163.com+86 15282135515;+86 15282135515

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026